| Literature DB >> 33209397 |
Nozomu Motono1, Shun Iwai1, Iijima Yoshihito1, Katsuo Usuda1, Sohsuke Yamada2, Hidetaka Uramoto1.
Abstract
BACKGROUND: The prognosis of non-small-cell lung cancer (NSCLC) patients with pleural dissemination is poor, and pleural dissemination is generally considered a contraindication for radical surgery. However, if pleural dissemination is missed intraoperatively, patients with false-negative stage IV NSCLC cannot receive appropriate chemotherapy, and their prognosis might worsen.Entities:
Keywords: Pleural dissemination; histological differentiation; non-small cell lung cancer (NSCLC); non-squamous cell carcinoma; young age
Year: 2020 PMID: 33209397 PMCID: PMC7656371 DOI: 10.21037/jtd-20-1543
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1Preoperative computed tomography. (A) Although pleural dissemination was suspected at interlobar fissure (arrow) on chest computed tomography, it was not found intraoperatively. (B) Although pleural dissemination was not clear at interlobar fissure (asterisk) on chest computed tomography, it was found intraoperatively.
Figure 2Flowchart of this study design.
Patients characteristics
| Outcome | |
|---|---|
| Gender (male/female) | 110/33 |
| Age (median, range) | 68 (38–89) |
| Smoking index (median, range) | 822 (0–3,660) |
| CEA (median, range) | 5.2 (0.7–403.3) |
| CTmax (median, range) | 40 (13–150) |
| Pmax (median, range) | 29 (3–244) |
| SUVmax (median, range) | 9.4 (0.89–37.9) |
| cT (1a/1b/1c/2a/2b/3/4) | 0/8/29/33/29/27/18 |
| cN (0/1/2) | 107/28/9 |
| cM (0/1a/1b) | 142/1/1 |
| cStage (0/1a1/1a2/1a3/1b/2a/2b/3a/3b/3c/4a/4b) | 0/0/7/26/28/22/27/32/1/1 |
| Histology (Ad/Sq/others) | 73/53/18 |
| G (1/2/3/4) | 35/61/38/10 |
| Pathomax (median, range) | 42 (10–240) |
| pT (1a/1b/1c/2a/2b/3/4) | 0/2/1/62/24/36/19 |
| pN (0/1/2) | 91/32/21 |
| pM (0/1a/1b) | 138/5/1 |
| pStage (0/1a1/1a2/1a3/1b/2a/2b/3a/3b/3c/4a/4b) | 0/0/1/0/40/20/33/0/5/1 |
| Dissemination (absent/present) | 137/7 |
| WBC (median, range) | 6,380 (2,980–12,150) |
| Plt (median, range) | 24.8 (12–54.8) |
| NLR (median, range) | 2.39 (0.53–9.23) |
| LDH (median, range) | 193 (133–448) |
| CRP (median, range) | 0.19 (0.03–45) |
CEA, carcinoembryonic antigen; CTmax, maximum tumor diameter on computed tomography; Pmax, tumor diameter adjacent to visceral pleura; SUVmax, maximum standardized uptake value; c; clinical; Ad, adenocarcinoma; Sq, squamous cell carcinoma; G, grade of differentiation; Pathomax, tumor diameter on pathological exam; p, pathological; WBC, white blood cell; Plt, platelet; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; CRP, C-reactive protein.
Relationship between pleural dissemination and clinicopathological variables
| Dissemination | P value | ||
|---|---|---|---|
| Present | Absent | ||
| Gender (male/female) | 5/2 | 105/32 | 0.72 |
| Age (median, range) | 62.8 (46–76) | 69.2 (38–89) | 0.05 |
| Smoking index (median, range) | 0 (0–3,660) | 825 (0–3,290) | 0.62 |
| CEA (median, range) | 8.8 (1.4–403.3) | 5.2 (0.7–306) | 0.65 |
| CTmax (median, range) | 40 (23–48) | 41 (13–150) | 0.58 |
| Pmax (median, range) | 25 (7–74) | 29 (3–244) | 0.71 |
| SUVmax (median, range) | 11.02 (4.8–13.68) | 9.37 (0.89–37.9) | 0.82 |
| cN (0/1-2) | 4/3 | 103/34 | 0.28 |
| Histology (Sq/non-Sq) | 0/7 | 53/84 | 0.03 |
| G (1-2/3-4) | 0/7 | 96/51 | <0.01 |
| Pathomax (median, range) | 42 (25–71) | 42 (10–240) | 0.72 |
| WBC (median, range) | 5,050 (4,160–8,640) | 6,440 (2,980–12,150) | 0.20 |
| Plt (median, range) | 24.4 (12–36.3) | 24.9 (12.4–54.8) | 0.73 |
| NLR (median, range) | 2.18 (1.3–7.45) | 2.41 (0.53–9.23) | 0.94 |
| LDH (median, range) | 210 (177–269) | 192 (133–448) | 0.23 |
| CRP (median, range) | 0.2 (0.03–3.66) | 0.18 (0.03–45) | 0.69 |
CEA, carcinoembryonic antigen; CTmax, maximum tumor diameter on computed tomography; Pmax, tumor diameter adjacent to visceral pleura; SUVmax, maximum standardized uptake value; c; clinical; Sq, squamous cell carcinoma; G, grade of differentiation; Pathomax, tumor diameter on pathological exam; WBC, white blood cell; Plt, platelet; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; CRP, C-reactive protein.
The clinicopathologic characteristics and the relationship between pleural dissemination and clinicopathological variables of these non-squamous cell carcinoma patients
| Dissemination | P value | ||
|---|---|---|---|
| Present | Absent | ||
| Gender (male/female) | 5/2 | 54/29 | 0.73 |
| Age (median, range) | 62.8 (46–76) | 68.2 (38–84) | 0.09 |
| Smoking index (median, range) | 0 (0–3,660) | 600 (0–2,800) | 0.96 |
| CEA (median, range) | 8.8 (1.4–403.3) | 5.2 (0.7–306) | 0.82 |
| CTmax (median, range) | 40 (23–48) | 36.5 (13–150) | 0.88 |
| Pmax (median, range) | 25 (7–74) | 28 (9–244) | 0.86 |
| SUVmax (median, range) | 11.02 (4.8–13.68) | 7.69 (0.89–37.9) | 0.22 |
| Histology (Ad/non-Ad) | 6/1 | 67/17 | 0.70 |
| G (1-2/3-4) | 0/7 | 59/25 | <0.01 |
| Pathomax (median, range) | 42 (25–71) | 40 (10–240) | 0.80 |
| WBC (median, range) | 5,050 (4,160–8,640) | 6,205 (2,980–11,300) | 0.42 |
| Plt (median, range) | 24.4 (12–36.3) | 24.6 (12.4–54.8) | 0.85 |
| NLR (median, range) | 2.18 (1.3–7.45) | 2.16 (0.53–9.23) | 0.80 |
| LDH (median, range) | 210 (177–269) | 192 (133–448) | 0.18 |
| CRP (median, range) | 0.2 (0.03–3.66) | 0.11 (0.03–18.14) | 0.93 |
CEA, carcinoembryonic antigen; CTmax, maximum tumor diameter on computed tomography; Pmax, tumor diameter adjacent to visceral pleura; SUVmax, maximum standardized uptake value; Ad, adenocarcinoma; G, grade of differentiation; Pathomax, tumor diameter on pathological exam; WBC, white blood cell; Plt, platelet; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; CRP, C-reactive protein.
Relationship between pleural dissemination and clinicopathological variables of non-squamous cell carcinoma patients divided by a receiver operating characteristics curve analysis
| Dissemination | P value | ||
|---|---|---|---|
| Present | Absent | ||
| Gender (male/female) | 5/2 | 54/30 | 0.70 |
| Age (<65/≥65) | 5/2 | 26/58 | 0.02 |
| Smoking index (<1,720/≥1,720) | 4/3 | 72/11 | 0.03 |
| CEA (<8.8/≥8.8) | 3/4 | 53/31 | 0.29 |
| CTmax (<48/≥48) | 7/0 | 59/25 | 0.09 |
| Pmax (<25/≥25) | 3 /4 | 31/53 | 0.75 |
| SUVmax (<8.8/≥8.8) | 1/6 | 46/38 | 0.03 |
| cN (0/1-2) | 4/3 | 66/18 | 0.19 |
| Histology (Ad /non-Ad) | 6/1 | 67/17 | 0.70 |
| G (1-2/3-4) | 0/7 | 59/25 | <0.01 |
| Pathomax (<45/≥45) | 5/2 | 48/36 | 0.46 |
| WBC (<5,190/≥5,190) | 4/3 | 25/59 | 0.13 |
| Plt (<17.1/≥17.1) | 1/6 | 8/76 | 0.68 |
| NLR (<5.02/≥5.02) | 5/2 | 78/6 | 0.05 |
| LDH (<177/≥177) | 0/7 | 26/58 | 0.08 |
| CRP (<0.13/≥0.13) | 3/4 | 43/41 | 0.67 |
CEA, carcinoembryonic antigen; CTmax, maximum tumor diameter on computed tomography; Pmax, tumor diameter adjacent to visceral pleura; SUVmax, maximum standardized uptake value; c, clinical; Ad, adenocarcinoma; G, grade of differentiation; Pathomax, tumor diameter on pathological exam; WBC, white blood cell; Plt, platelet; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; CRP, C-reactive protein.
Logistic regression analysis
| Variables | Likelihood rate chi-square value | P value |
|---|---|---|
| Age (<65/≥65) | 5.6418 | 0.01 |
| Smoking index (<1,720/≥1,720) | 2.5796 | 0.11 |
| SUVmax (<8.8/≥8.8) | 0.0005 | 0.93 |
| G (1-2/3-4) | 8.4379 | <0.01 |
SUVmax, maximum standardized uptake value; Ad, adenocarcinoma; G, grade of differentiation.